The samples in our patient cohort stemmed from melanoma, bladder, renal cell, and gastric cancer suggesting that the loss of mismatch-repair genes could also enhance sensitivity to anti-PD-1 therapy in these tumor types. This evidence concerns the gene PDCD1 and melanoma.